Ensysce Biosciences Releases "Highlights Video" of PAINWeek 2023 Symposium
- Ensysce Biosciences announces the release of a video showcasing its PAINWeek Symposium on PF614 and PF614-MPAR treatments. The event featured leading authorities on pain and drug development, who believe these treatments have the potential to be the 'next generation' of analgesics.
- None.
~ A showcase of PF614 and PF614-MPAR ~
SAN DIEGO, CA / ACCESSWIRE / October 13, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced it has posted to the Company's Corporate and Investor Relations website a video highlighting its PAINWeek Symposium entitled, "Severe Pain, Next Generation Solutions: PF614 / PF614-MPAR" held in Las Vegas on Sept 7, 2023.
The "Highlights Video" features Dr. Jeff Gudin, University of Miami, School of Medicine Faculty of Anesthesiology and Pain Management, Dr. Richard Dart, Director of the Rocky Mountain Poison and Drug Center, and Dr. William Schmidt, Chief Medical Officer of Ensysce Biosciences, three leading authorities on pain, opioid use and drug development, and their perspectives of PF614 and PF614-MPAR treatments as well-positioned to become the ‘next generation' of analgesics.
"We are pleased to share this short summary of the PAINWeek event, attended by over 400 experts in the field. This meeting provided an expansive platform to share the notable clinical progress of our two lead programs which we believe provide the promise of a novel approach to safer solutions for patients in pain." said Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce Biosciences.
About Ensysce Biosciences
Ensysce Biosciences is a clinical-stage company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAPTM) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.
Forward-Looking Statements
Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from its fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent quarterly report on Form 10-Q and current reports on Form 8-K, which are available, free of charge, at the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.
Ensysce Biosciences Company Contact:
Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196
Ensysce Biosciences Investor Relations Contact:
Shannon Devine
MZ North America
Main: 203-741-8811
ENSC@mzgroup.us
SOURCE: Ensysce Biosciences Inc.
View source version on accesswire.com:
https://www.accesswire.com/792545/ensysce-biosciences-releases-highlights-video-of-painweek-2023-symposium
FAQ
What is Ensysce Biosciences showcasing in the video?
Who were the speakers at the symposium?
What is the potential of PF614 and PF614-MPAR treatments?
